Trial Outcomes & Findings for Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis. (NCT NCT01135186)
NCT ID: NCT01135186
Last Updated: 2019-09-10
Results Overview
Gastric Accommodation refers to the reflexive relaxation of the upper stomach after swallowing as measured by the Satiety Test at baseline, 4 weeks, and 8 weeks. Increased gastric accommodation is considered a positive outcome.
COMPLETED
NA
9 participants
Baseline, 4 Weeks, 8 Weeks
2019-09-10
Participant Flow
9 women with moderate to severe gastroparesis were enrolled at medical clinic.
Participant milestones
| Measure |
Open Label Study
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
|
|---|---|
|
Overall Study
STARTED
|
9
|
|
Overall Study
COMPLETED
|
9
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Baseline characteristics by cohort
| Measure |
Open Label Study
n=9 Participants
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day (week 1 through week 4)
sapropterin dihydrochloride: sapropterin dihydrochloride: 20mg/kg/day (week 5 through week 8)
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
9 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Age, Continuous
|
42.56 years
STANDARD_DEVIATION 15.03 • n=99 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
|
Region of Enrollment
United States
|
9 participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Baseline, 4 Weeks, 8 WeeksGastric Accommodation refers to the reflexive relaxation of the upper stomach after swallowing as measured by the Satiety Test at baseline, 4 weeks, and 8 weeks. Increased gastric accommodation is considered a positive outcome.
Outcome measures
| Measure |
Open Label Study
n=9 Participants
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
|
|---|---|
|
Gastric Accommodation
Baseline
|
322.22 ml
Standard Deviation 137.18
|
|
Gastric Accommodation
4 Weeks
|
402.78 ml
Standard Deviation 197.03
|
|
Gastric Accommodation
8 Weeks
|
450.63 ml
Standard Deviation 301.50
|
SECONDARY outcome
Timeframe: Baseline, 4 Weeks, 8 WeeksChange in symptom severity over the past 2 weeks as measured by the patient reported Gastroparesis Cardinal Symptom Index (GCSI) The GCSI is composed of 9 questions. Each question asks about symptom severity on a scale of 1-5 listed below. 0=None 1= Very mild 2= Mild 3=Moderate 4=Severe 5= Very severe The 9 scores are summed together for cumulative GCSI score. The minimum cumulative score is '"0" and the maximum cumulative score is "45." Once we calculated the cumulative score for each participant, we took the average of all participants cumulative scores giving us the sample mean. This was done at baseline, week 4, and week 8. Higher total scores indicate higher symptom severity. Lower total scores indicate lower symptom severity.
Outcome measures
| Measure |
Open Label Study
n=9 Participants
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
|
|---|---|
|
Secondary Outcome Measures Will Include Change in Symptom Severity.
Baseline
|
32.00 units on a scale
Standard Deviation 8.67
|
|
Secondary Outcome Measures Will Include Change in Symptom Severity.
4 Weeks
|
23.25 units on a scale
Standard Deviation 13.91
|
|
Secondary Outcome Measures Will Include Change in Symptom Severity.
8 Weeks
|
23.67 units on a scale
Standard Deviation 13.91
|
SECONDARY outcome
Timeframe: Baseline, 4 Weeks, 8 WeeksQuality of life as impacted by patients with upper gastrointestinal disorders (PAGI-QOL) The PAGI-QOl is composed of 30 questions. Each question asks about the degree to which a patient's quality of life is impacted by upper gastrointestinal disorders. Questions measure quality of life impact on a scale of 1-5 listed below. 0=none of the time, 1=a little of the time, 2=some of the time, 3=a good bit of the time, 4= most of the time, 5= all of time The 30 items are summed together for a cumulative PAGI-QOL score. The minimum cumulative score is "0" and the maximum score is "150." Once we calculated the cumulative score for each participant, we took the average of all participants cumulative scores giving us the sample mean. This was done at baseline, week 4, and week 8. Lower scores indicate an improved overall quality of life. Higher scores indicate a diminished overall quality of life.
Outcome measures
| Measure |
Open Label Study
n=9 Participants
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
|
|---|---|
|
Secondary Outcome Measures Will Include Change in Quality of Life.
Baseline
|
91.22 units on a scale
Standard Deviation 28.27
|
|
Secondary Outcome Measures Will Include Change in Quality of Life.
4 Weeks
|
61.29 units on a scale
Standard Deviation 37.83
|
|
Secondary Outcome Measures Will Include Change in Quality of Life.
8 Weeks
|
60.50 units on a scale
Standard Deviation 40.90
|
SECONDARY outcome
Timeframe: Baseline, 4 Weeks, 8 WeeksSymptom severity as measured by the Patient Assessment of Upper Gastrointestinal Disorder- Symptom Severity Index. (PAGI-SYM) The PAGI-SYM is compose of 20 questions. Each question can be answered on a scale of 1-5 (below) 0 = none, 1=very mild, 2=mild, 3=moderate, 4=severe, 5=very severe Cumulative scores were calculated by summing all 20 questions. The minimum cumulative scores would be "0" while the maximum cumulative score would be "100" Once we calculated the cumulative score for each participant, we took the average of all the cumulative scores giving us the sample mean. This was done at baseline, week 4, and week 8. Lower score indicates decreased symptom severity. Higher score indicates increased symptom severity.
Outcome measures
| Measure |
Open Label Study
n=9 Participants
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
|
|---|---|
|
Secondary Outcome Measures Will Include Change in Symptom Severity as Measured by the Patient Assessment of Gastrointestinal Disorder-Symptom Severity Index Disorders Symptom Severity Index (PAGI-SYM)
Baseline
|
54.89 units on a scale
Standard Deviation 17.14
|
|
Secondary Outcome Measures Will Include Change in Symptom Severity as Measured by the Patient Assessment of Gastrointestinal Disorder-Symptom Severity Index Disorders Symptom Severity Index (PAGI-SYM)
4 Weeks
|
41.50 units on a scale
Standard Deviation 23.08
|
|
Secondary Outcome Measures Will Include Change in Symptom Severity as Measured by the Patient Assessment of Gastrointestinal Disorder-Symptom Severity Index Disorders Symptom Severity Index (PAGI-SYM)
8 Weeks
|
34.50 units on a scale
Standard Deviation 19.71
|
Adverse Events
Open Label Study
Serious adverse events
| Measure |
Open Label Study
n=9 participants at risk
sapropterin dihydrochloride
sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day (week 1-4) 20 mg/kg/day (week 5-8)
|
|---|---|
|
Gastrointestinal disorders
Hospitalization for gastroparesis flareup
|
11.1%
1/9 • Number of events 1
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place